Cogent Biosciences, Inc.
COGT
$34.10
-$0.27-0.79%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -26.64% | -10.07% | -2.14% | -5.98% | 3.83% |
| Total Depreciation and Amortization | -0.52% | -0.86% | 1.67% | 2.71% | 1.00% |
| Total Amortization of Deferred Charges | -34.44% | -- | -- | -- | -- |
| Total Other Non-Cash Items | 110.87% | 3.79% | 10.41% | 22.79% | 77.32% |
| Change in Net Operating Assets | -97.23% | -39.25% | 266.14% | -316.98% | -108.44% |
| Cash from Operations | -23.05% | -17.87% | 18.00% | -9.80% | -16.53% |
| Capital Expenditure | -1,147.69% | 50.38% | 76.05% | -629.33% | 73.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -107.74% | -1,814.20% | -87.07% | 13.25% | 2.12% |
| Cash from Investing | -108.18% | -1,840.13% | -87.16% | 12.50% | 2.47% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -2,740.65% | 200.00% | -- | -- | -- |
| Issuance of Common Stock | 113.29% | 32,793.90% | -97.18% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -53.69% | -2,272.00% | -- | -- | -- |
| Cash from Financing | 170.82% | 360.26% | 89.13% | 95,938.46% | -95.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9,606.11% | -223.20% | -94.27% | 2,385.54% | -87.31% |